Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 11, Number 8—August 2005

Research

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use

Conan MacDougall*, Spencer E. Harpe*, J. Patrick Powell*, Christopher K. Johnson†, Michael B. Edmond*, and Ron E. Polk*Comments to Author 
Author affiliations: *Virginia Commonwealth University, Richmond, Virginia, USA; †Idaho State University, Boise, Idaho, USA

Main Article

Figure 1

Fluoroquinolone use and resistance over study period. FQ, fluoroquinolone; Levo, levofloxacin; Cipro, ciprofloxacin; Moxi, moxifloxacin; Gati, gatifloxacin; DDD/1,000PD, defined daily doses/1,000 patient-days; FQ-R PSA, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

Figure 1. . Fluoroquinolone use and resistance over study period. FQ, fluoroquinolone; Levo, levofloxacin; Cipro, ciprofloxacin; Moxi, moxifloxacin; Gati, gatifloxacin; DDD/1,000PD, defined daily doses/1,000 patient-days; FQ-R PSA, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external